Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016, Article ID 4381513, 9 pages
http://dx.doi.org/10.1155/2016/4381513
Research Article

Genetic Abnormalities in Biliary Brush Samples for Distinguishing Cholangiocarcinoma from Benign Strictures in Primary Sclerosing Cholangitis

1Department of Gastroenterology and Hepatology, Academic Medical Center, 1100 DD Amsterdam, Netherlands
2Center for Experimental and Molecular Medicine, Academic Medical Center, 1100 DD Amsterdam, Netherlands
3Department of Pathology, Academic Medical Center, 1100 DD Amsterdam, Netherlands

Received 21 December 2015; Accepted 22 February 2016

Academic Editor: Keiichi K. Kubota

Copyright © 2016 Margriet R. Timmer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. A. Abrendt, H. A. Pitt, A. Nakeeb et al., “Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis,” Journal of Gastrointestinal Surgery, vol. 3, no. 4, pp. 357–368, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Boonstra, R. K. Weersma, K. J. van Erpecum et al., “Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis,” Hepatology, vol. 58, no. 6, pp. 2045–2055, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. M. H. Chapman, G. J. M. Webster, S. Bannoo, G. J. Johnson, J. Wittmann, and S. P. Pereira, “Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience,” European Journal of Gastroenterology and Hepatology, vol. 24, no. 9, pp. 1051–1058, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Sinakos, A. K. Saenger, J. Keach, W. R. Kim, and K. D. Lindor, “Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19–9 do not have cholangiocarcinoma,” Clinical Gastroenterology and Hepatology, vol. 9, no. 5, pp. 434.e1–439.e1, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Halme, J. Arola, K. Numminen, L. Krogerus, H. Mäkisalo, and M. Färkkilä, “Biliary dysplasia in patients with primary sclerosing cholangitis: additional value of DNA ploidity,” Liver International, vol. 32, no. 5, pp. 783–789, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. P. G. K. Venkatesh, U. Navaneethan, B. Shen, and A. J. McCullough, “Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma,” Digestive Diseases and Sciences, vol. 58, no. 3, pp. 850–857, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Y. Ponsioen, S. M. E. Vrouenraets, A. W. M. van Milligen de Wit et al., “Value of brush cytology for dominant strictures in primary sclerosing cholangitis,” Endoscopy, vol. 31, no. 4, pp. 305–309, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. P. S. Furmanczyk, V. S. Grieco, and S. N. Agoff, “Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: evaluation of specific cytomorphologic features and CA19-9 levels,” American Journal of Clinical Pathology, vol. 124, no. 3, pp. 355–360, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. L. E. Moreno Luna, B. Kipp, K. C. Halling et al., “Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures,” Gastroenterology, vol. 131, no. 4, pp. 1064–1072, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Charatcharoenwitthaya, F. B. Enders, K. C. Halling, and K. D. Lindor, “Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis,” Hepatology, vol. 48, no. 4, pp. 1106–1117, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Bergquist, B. Tribukait, H. Glaumann, and U. Broomé, “Can DNA cytometry be used for evaluation of malignancy and premalignancy in bile duct strictures in primary sclerosing cholangitis?” Journal of Hepatology, vol. 33, no. 6, pp. 873–877, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. S. C. McKay, K. Unger, S. Pericleous et al., “Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma,” HPB, vol. 13, no. 5, pp. 309–319, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Wang, X. Wang, S. Xie et al., “P53 status and its prognostic role in extrahepatic bile duct cancer: a meta-analysis of published studies,” Digestive Diseases and Sciences, vol. 56, no. 3, pp. 655–662, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. M. R. Timmer, U. Beuers, P. Fockens et al., “Genetic and epigenetic abnormalities in primary sclerosing cholangitis-associated cholangiocarcinoma,” Inflammatory Bowel Diseases, vol. 19, no. 8, pp. 1789–1797, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Jaiswal, N. F. LaRusso, and G. J. Gores, “Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 281, no. 3, pp. G626–G634, 2001. View at Google Scholar · View at Scopus
  16. E. P. Berthiaume and J. Wands, “The molecular pathogenesis of cholangiocarcinoma,” Seminars in Liver Disease, vol. 24, no. 2, pp. 127–137, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Komori, H. Marusawa, T. Machimoto et al., “Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma,” Hepatology, vol. 47, no. 3, pp. 888–896, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. U. Navaneethan, B. Njei, P. G. K. Venkatesh, J. J. Vargo, and M. A. Parsi, “Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis,” Gastrointestinal Endoscopy, vol. 79, no. 6, pp. 943–950.e3, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. T. A. Gonda, M. P. Glick, A. Sethi et al., “Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures,” Gastrointestinal Endoscopy, vol. 75, no. 1, pp. 74–79, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. L. E. Vasilieva, S. I. Papadhimitriou, A. Alexopoulou et al., “An extended fluorescence in situ hybridization approach for the cytogenetic study of cholangiocarcinoma on endoscopic retrograde cholangiopancreatography brushing cytology preparations,” Human Pathology, vol. 44, no. 10, pp. 2173–2179, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. C. C. Maley, P. C. Galipeau, J. C. Finley et al., “Genetic clonal diversity predicts progression to esophageal adenocarcinoma,” Nature Genetics, vol. 38, no. 4, pp. 468–473, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. S. A. Ahrendt, C. F. Eisenberger, L. Yip et al., “Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma,” Journal of Surgical Research, vol. 84, no. 1, pp. 88–93, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Shiraishi, K. Okita, N. Kusano et al., “A comparison of DNA copy number changes detected by comparative genomic hybridization in malignancies of the liver, biliary tract and pancreas,” Oncology, vol. 60, no. 2, pp. 151–161, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Taniai, H. Higuchi, L. J. Burgart, and G. J. Gores, “p16 INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma,” Gastroenterology, vol. 123, no. 4, pp. 1090–1098, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Ukita, M. Kato, and T. Terada, “Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry,” Journal of Hepatology, vol. 36, no. 6, pp. 780–785, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. J.-Y. Lee, Y.-N. Park, K.-O. Uhm, S.-Y. Park, and S.-H. Park, “Genetic alterations in intrahepatic cholangiocarcinoma as revealed by degenerate oligonucleotide primed PCR-comparative genomic hybridization,” Journal of Korean Medical Science, vol. 19, no. 5, pp. 682–687, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Nakazawa, Y. Dobashi, S. Suzuki, H. Fujii, Y. Takeda, and A. Ooi, “Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers,” The Journal of Pathology, vol. 206, no. 3, pp. 356–365, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. M. B. Cohen, R. J. Wittchow, F. C. Johlin, K. Bottles, and S. S. Raab, “Brush cytology of the extrahepatic biliary tract: comparison of cytologic features of adenocarcinoma and benign biliary strictures,” Modern Pathology, vol. 8, no. 5, pp. 498–502, 1995. View at Google Scholar · View at Scopus
  29. A. A. Renshaw, R. Madge, M. Jiroutek, and S. R. Granter, “Bile duct brushing cytology: statistical analysis of proposed diagnostic criteria,” American Journal of Clinical Pathology, vol. 110, no. 5, pp. 635–640, 1998. View at Google Scholar · View at Scopus
  30. A. M. Rygiel, J. W. P. M. Van Baal, F. Milano et al., “Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population,” Cancer, vol. 109, no. 10, pp. 1980–1988, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. X. Li, P. C. Galipeau, T. G. Paulson et al., “Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus,” Cancer Prevention Research, vol. 7, no. 1, pp. 114–127, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. E. G. Barr Fritcher, J. S. Voss, S. M. Brankley et al., “An optimized set of fluorescence in situ hybridization probes for detection of pancreatobiliary tract cancer in cytology brush samples,” Gastroenterology, vol. 149, no. 7, pp. 1813.e1–1824.e1, 2015. View at Publisher · View at Google Scholar
  33. L. Soucek and G. I. Evan, “The ups and downs of Myc biology,” Current Opinion in Genetics and Development, vol. 20, no. 1, pp. 91–95, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Yang, T. W. H. Li, J. Peng et al., “A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression,” Gastroenterology, vol. 141, no. 1, pp. 378.e4–388.e4, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. S. A. Ahrendt, A. Rashid, J. T. Chow, C. F. Eisenberger, H. A. Pitt, and D. Sidransky, “p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer,” Journal of Hepato-Biliary-Pancreatic Surgery, vol. 7, no. 4, pp. 426–431, 2000. View at Publisher · View at Google Scholar · View at Scopus